Clinical trials: Liver Tumour
Immune-Mediated Hepatitis, Liver Failure
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
This study aims to investigate the efficacy and safety of artificial liver support system treatment for immune checkpoint inhibitors related liver failure in patients with hepatocellular carcinoma.
- Conditions
- Immune-Mediated Hepatitis, Liver Failure, Hepatocellular Carcinoma
- Trial name
- NCT05484908
- Testing
- DPMAS+LPE, PE, Comprehensive internal medical treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Solid Tumor, Hepatocellular Carcinoma
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with Other Therapy in Subjects with Advanced Solid Tumors
- Conditions
- Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer, NSCLC
- Trial name
- NCT04780217
- Testing
- T3011
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- ImmVira Pharma Co. Ltd
Hepatocellular Carcinoma
Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma
The objective of this study is to evaluate the efficacy and safety of Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients in hepatocellular carcinoma.
- Trial name
- NCT03857815
- Testing
- anti-PD-1 antibody
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatic Impairment, Advanced Malignant Solid Tumor
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat. The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe…
- Trial name
- NCT04241835
- Testing
- Tazemetostat
- Where
- 14 sites in United States, Belgium and 3 more
- Volunteers
- 18 people
- Sponsor
- Epizyme, Inc.
Liver Cancer, Hepatic Tumors
Follow-up Yttrium-90 Internal Pair Production PET/CT vs Brehmsstrahlung Imaging in Patients With Primary/Metastatic Liver Tumors
This is a prospective non-blinded case series involving the acquisition of a pair production PET/CT as soon as possible after an already performed Y-90 Sirspheres treatment of hepatic malignancy.
- Trial name
- NCT02202317
- Testing
- PET/CT Scan
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Miami
Liver Diseases, Digestive System Diseases
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
This is a Phase 1, multicenter, nonrandomized, open-label, parallel-group study in participants with mild or moderate hepatic impairment, and in participants with normal hepatic function.
- Trial name
- NCT04639115
- Testing
- Ozanimod
- Where
- 3 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Celgene
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have advanced cancer and liver…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
- Trial name
- NCT00025415
- Testing
- imatinib mesylate, pharmacological study
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Prostate Cancer
Survivorship Promotion In Reducing IGF-1 Trial
This is a prospective, single-center randomized trial with three arms, and an allocation ratio of 1:1:1. The study design is an efficacy study to evaluate the effect of metformin and coach-directed behavioral weight loss versus…
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer
- Trial name
- SPIRIT (NCT02431676)
- Testing
- Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Carcinoma, Hepatocellular
RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode
The purpose of this study is to prospectively compare the clinical outcomes (local tumor progression rate, technical success rate, complication rate) of no touch radiofrequency ablation (RFA) technique for Hepatocellular…
- Trial name
- NCT02806076
- Testing
- No-touch RFA arm, Conventional tumor puncture RFA arm
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Advanced Liver Cancers
Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers
The treatment of liver cancer needs integrated medical strategies, including surgery, chemotherapy, target therapy, radiotherapy, and immunotherapy.
- Trial name
- NCT05622825
- Testing
- DC-CIK
- Volunteers
- 15 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma (HCC), Cirrhosis
mSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients With Cirrhosis
This study aims to evaluate the role of the circulating epigenetic biomarker mSEPT9 in predicting the risk of hepatocellular carcinoma (HCC) in patients with cirrhosis.
- Conditions
- Hepatocellular Carcinoma (HCC), Cirrhosis, Risk Prediction for Liver Cancer, Epigenomics
- Trial name
- SEPT9_SuRV (NCT06778317)
- Testing
- Circulating mSEPT9 Biomarker Testing
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Central Hospital, Nancy, France
Liver Cancer
DX-8951f in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have liver cancer.
- Trial name
- NCT00004108
- Testing
- exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo
Hepatocellular Carcinoma
Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma
In this study, safety and effects of IPM001 vaccine on human hepatocellular carcinoma are going to be investigated, IPM001 is a neoantigen/tumor-specific antigen sensitized autoimmune cell injection
- Trial name
- NCT05105815
- Testing
- IPM001
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Huashan Hospital
Solid Tumors, Non-small Cell Lung Cancer
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
This is an open-label, multi-center study of Phase Ib/II study to assess the efficacy and safety of Envafolimab combinded with Lenvatinib in the treatment of subjects with advanced solid tumors.
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05024214
- Testing
- Lenvatinib + Envafolimab, Sunitinib
- Where
- 23 sites in China
- Volunteers
- 170 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients
This study consists of two parts: Phase I is a dose escalation study to determine the Recommended Phase II Dose (RP2D) of MGD013 monotherapy and that of MGD013 when in combination with Brivanib Alaninate (ZL-2301) in subjects…
- Trial name
- NCT04212221
- Testing
- MGD013 monotherapy, MGD013 in combination with Brivanib Alaninate
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00658593
- Testing
- capecitabine, gemcitabine hydrochloride, quality-of-life assessment
- Where
- 8 sites in Canada
- Volunteers
- 19 people
- Sponsor
- NCIC Clinical Trials Group
Hepatocellular Carcinoma
Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver: Case-control Study (NoFlic Study)
The main objective of this study is to identify direct carcinogenic factors in the absence of cirrhosis, and the carcinogenesis pathways involved on nonfibrotic liver (NfCHC).
- Trial name
- NoFlic (NCT03852238)
- Testing
- Blood test and self-administrated questionnaires
- Where
- 14 sites in France
- Volunteers
- 283 people
- Sponsor
- University Hospital, Bordeaux
Liver Metastases, Colorectal Cancer Metastatic
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus regorafenib for patients with colorectal cancer liver metastasis in the third-line setting.
- Trial name
- NCT05057052
- Testing
- Sintilimab, Regorafenib, US/CT-guided Percutaneous Cryoablation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver
European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)
The EU-PNAFLD (The European Paediatric NALFD Registry) will be a network composed of European centres involved in the care of children with NAFLD, and will include Hepatologists, Endocrinologists, and Scientists, supported by…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
- Trial name
- EU-PNAFLD (NCT04190849)
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells.
- Conditions
- Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00002515
- Testing
- filgrastim, carboplatin, thiotepa
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.